Podcasts about pharmd

The longevity industry is booming. Influencers are promoting this and that as promoting healthy aging, longevity, and healthspan, and it's hard for us, much less our patients, to make sense of it.  To be sure, we should always start by recommending exercise, nutritious foods, good sleep habits, and meaningful social interaction.  We wanted to go beyond that to talk about the promise and potential and risks/harms of "biohacks." Today we talk with Mahtab Jafari, PharmD, and John Newman, MD, PhD, and to discuss: How we clinicians should think about this movement, knowing many of our patients (and ourselves) also prize living as long as we can as healthy as we can, and at the same time acknowledge that a high quality of life, growth, and a meaningful life are possible with support in states of disability or dementia. How animal models can leading to promising therapeutics but must be tested in humans What it takes for a drug to obtain approval for longevity or healthspan indications when we cannot realistically wait around 40 years for a result We ask them to rate the evidence for many treatment on the scale of very promising, meh, or snake oil/avoid, including creatine, metformin, GLP1, SGLT2i, NAD+, testosterone/estrogen, red light therapy, rapamycin, and rodeola rosea. And I get to sing Wake Me Up by Avicii - an uplifting song with lyrics that could have multiple meanings - makes you think! -Alex Smith

Join us as we explore the journey of lifelong learning in healthcare with Pharmacist Dr. Jim Ferrell! Discover his pearls of medication management and how curiosity and a passion for medicine shaped his career in pharmacy and patient care.Key takeaways:·       Jim's background in healthcare and family ties to the field.·       The importance of lifelong learning and curiosity inprofessional growth.·       Insights into the challenges and rewards of working in pharmacy.·       How personal experiences with patients can shape a clinician'sapproach.·       The role of pharmacists in patient care and medicationmanagement.

What does it take to move from fixing one broken corner of healthcare to reimagining the whole thing? On this episode of Astonishing Healthcare, host Justin Venneri sits down with two of his favorite guests together for the first time: Judi Health's CEO, AJ Loiacono, and Chief Commercial Officer, Kristin Begley, PharmD.The catalyst for this special episode is the company's rebrand, the evolution from Capital Rx, the transparent PBM that built Judi®, into Judi Health, a unified health technology company. AJ and Kristin explain why the "Rx" designation remains a core piece of the company's identity but no longer fully reflects the organization's evolving mission. They also describe the difference between "little T" transparency and the real thing, why incentive alignment matters so much, and what it took to build the first platform to process medical, pharmacy, dental, and vision claims on one system. They also express gratitude to the team and share bold predictions for where health benefits go next.Key TakeawaysThe rebrand reflects an expanded mission, not a new one. Capital Rx launched as a transparent PBM, with "Rx" signaling its focus on pharmacy. Over eight years, the company broadened its administrative capabilities, including medical claims processing, and much more - all powered by Judi. Thus, the primary brand: Judi Health, with services harmonized as Judi Rx (pharmacy), Judi Care (medical administration, TPA, navigation), and Judi Cloud (platform licensing for health plans and TPAs).There's a real difference between "little T" transparency and true transparency. AJ argues that true transparency means an auditable workflow: full disclosure of all compensation, proof that every customer receives the same pricing and benefit, and no hidden earnings. He calls out the "little H" holding company trick and explains why alignment yields better outcomes for plans and their members.‍Nobody had built unified claims processing before. AJ recalls initial skepticism around unified claims. His response: "If Netflix had kept mailing DVDs, we wouldn't be talking about Netflix." To date, no other organization has built a unified claims processing platform. Judi is the exception.Unified claims processing will become the standard. Once employers realize they have options, markets shift quickly. AJ, who predicted the rise of transparent PBMs, makes a new call: unified claims will be the industry norm.Related ContentJudi Health™ Announces Capital Rx is Now Judi Rx™, Launches Judi Care™ and Judi Cloud™ to Power the Next Era of Health Benefits Administration and Patient CareAH100 - The End of the Age of Confusion, It's Time for Acceptance, with AJ LoiaconoAH067 - Aligned Health Benefits and the Freedom to Unbundle, with Kristin Begley, PharmDWhat is a Core Administrative Processing System (CAPS) in Healthcare Payer Operations?AH111 - Building a Single Source of Truth for Medical and Pharmacy Benefits, with Kevin Sundquist & Liya LomsadzeFor more information about this episode, please visit Judi Health Insights.

Navigating Treatment, Access, and Outcomes in Idiopathic Hypersomnia On this episode guest host Denise Wolff, PharmD, CEO & Founder of Denise & Co., LLC, welcomes Zachary Contreras, PharmD, RPh, Director of Pharmacy Benefits, Sharp Health Plan, for a discussion on idiopathic hypersomnia (IH), a chronic neurological sleep disorder that remains widely underrecognized despite its profound impact on patients' lives. Together, they explore the challenges of diagnosing IH, including a diagnostic delay that can exceed a decade, the significant burden the condition places on work, relationships, education, and overall quality of life, and the reasons many patients remain invisible within healthcare systems. The episode highlights practical steps health plans can take today to reduce barriers to care, improve long-term outcomes, and help patients with idiopathic hypersomnia receive the diagnosis and treatment they need sooner. Sponsored by Jazz Pharmaceuticals.

Send us Fan MailSend us Fan MailSchedule an Rx AssessmentWhat if your team held the best ideas for growing your pharmacy and you just needed to get out of the way?On this episode of the Bottom Line Pharmacy Podcast, we sit down with Dr. Jay Phipps, owner of Phipps Pharmacy and founder of the Phipps Tank concept, to break down:What Phipps Tank is and how to run it in your pharmacyWhy culture is a bottom line strategy, not just a feel-good initiativeHow psychological safety drives team performance and real revenue growthWhy your fear of change might be your biggest financial liabilityAnd more!More About Our Guest: Dr. Jay Phipps is a Pharmacy Gladiator, Pharmacy Doctor, Founder, Entrepreneur President, and CEO with over 29 years of experience in pharmacy. At Phipps Pharmacy, Dr. Jay leads a team of dedicated and professional Pharmacy Doctors and technicians who provide personalized and high-quality care for patients. Phipps Pharmacy, Inc. is an independent pharmacy with 5 locations in Tennessee and Mississippi. Dr. Jay is also the President and CEO of PhippsCare that focuses on Pharmacy Doctor provided healthcare and Health Insurance Solutions who specializes in medical and pharmacy plans for seniors. Dr. Jay currently serves on multiple Boards of Directors and committees on the national, state, and local levels. He has served as the American Pharmacist Association-Academy Students of Pharmacy National President, on the APhA Board of Trustees, President of the Tennessee Pharmacists Association (TPA), on the Board of Directors for TPA, Chair, Tennessee Pharmacy Research Education Foundation, Co-Chair, Carroll County Drug Prevention Coalition and a District 8 County Commissioner. Dr. Phipps received a Doctor of Pharmacy degree from The University of Tennessee Health Science Center, where he also completed a residency in Drug Information and Pharmacotherapy and is currently pursuing an MBA with a major in Leadership and Strategy from the #1 ranked online MBA program at Indiana University - Kelley School of Business.  Dr. Phipps plans to graduate in the fall of 2024. Connect with Dr. Jay Phipps, PharmD:Jay Phipps LinkedInPharmacy Gladiator WebsitePharmacy Gladiator InstagramPharmacy Gladiator TikTokPharmacy Gladiator YouTubeStay connected with us:FacebookTwitterLinkedInScotty Sykes – CPA, CFP LinkedInScotty Sykes – CPA, CFP TwitterBonnie Bond – CPA LinkedInBonnie Bond – CPA Twitter More resources on this topic: Podcast - Becoming a Pharmacy GladiatorPodcast – Driving Independent Pharmacy Profitability in 2026 with Nicolette Mathey, PharmD, CEO of Atrium24Podcast – 2026 Quarter 2 Pharmacy UpdatePodcast – America 250, The history of Pharmacy, Q&A

Cash-Pay Generic Drugs Are a Functioning Market in Healthcare, and Policymakers Could Break It. Episode 520. Cash-pay generic drugs are one of the few corners of US healthcare where a real, functioning market already exists — which is why Stacey Richter argues policymakers need to tread carefully when trying to "fix" drug affordability. In this solo episode, Stacey explains why cash generic prices can run as low as $1 a prescription, then plays clips from four past guests — Ge Bai, PhD, CPA; Bryce Platt, PharmD; Benjamin Jolley, PharmD; and Luke Slindee, PharmD — showing how inserting a PBM extracts $41 out of every $100 spent, leaving patients paying more for the "privilege" of using their insurance. WHAT YOU'LL LEARN ✅ Why cash-pay generic drugs are one of the few genuinely functioning markets left in US healthcare, with multisource manufacturer competition keeping prices as low as $1 to $18 per prescription ✅ Why using insurance/PBM coverage makes the 20 most prescribed generics more expensive 43% of the time overall, and up to 79% of the time in the deductible phase, per Ge Bai, PhD, CPA's research in Annals of Internal Medicine ✅ How PBMs extract $41 out of every $100 spent on generic drugs that cost roughly 47 cents to manufacture, largely through the administrative overhead of risk pooling ✅ How Most Favored Nation "lesser of" clauses in PBM-pharmacy contracts punish pharmacies for lowering their cash prices, and why Luke Slindee, PharmD, argues removing that single clause could unlock a more robust cash-pay market without pulling generics from insurance entirely ✅ Why generic drug adoption has slowed from about one month to six months to reach peak uptake, which Bryce Platt, PharmD, ties to PBM formulary control rather than reduced competition or prescriber resistance ✅ Four policy ideas Stacey floats for keeping generics affordable without wrecking the underlying market: eliminating MFN clauses, funded wallets or prepaid cards, pre-funded cash-pay pharmacy relationships, and removing generics from PBM adjudication entirely WHY THIS MATTERS Generic drugs are one of the only truly functioning markets left in US healthcare, and cash prices are already low because of it. But policymakers trying to make medications more affordable often reach for the same lever — routing everything through insurance/PBM adjudication — which the data shows frequently raises what patients pay while handing PBMs a 41-cent cut of every dollar spent. As Stacey puts it, "you have to be really careful what levers you push because you can't see what they're attached to," and the wrong fix could break the one part of healthcare that's actually working. MENTIONED IN THIS EPISODE EP444 with Ann Kempski: Apple Podcasts | Spotify | Other Apps LinkedIn Post by Bryce Platt, PharmD EP495 with Mick Connors, MD: Apple Podcasts | Spotify | Other Apps EP420 with Ge Bai, PhD, CPA: Apple Podcasts | Spotify | Other Apps EP422 with Benjamin Jolley, PharmD: Apple Podcasts | Spotify | Other Apps EP517 with Stacey: Apple Podcasts | Spotify | Other Apps LinkedIn Post by Bryce Platt, PharmD EP439 with Luke Slindee, PharmD: Apple Podcasts | Spotify | Other Apps LinkedIn Post by Patrick Moore EP465 with Chris Crawford: Apple Podcasts | Spotify | Other Apps === LINKS ===

Host Dr. Jay Anders welcomes Anna Dover, PharmD, Senior Director of Editorial Content at First Databank (FDB). Together they unpack pharmacogenomics — using a patient's genetic profile to predict which drugs will work and which will cause harm — and why it's one of the most exciting frontiers in personalized medicine. They explore the data challenges holding it back, from genetic results trapped in unstructured PDFs to the lack of a standard transmission vocabulary and the gap between health system and community pharmacy. Dover also details FDB's new MCP for grounding large language models in evidence-based, clinically curated drug information.

Healthy skin starts with calming inflammation and supporting your skin barrier! In this episode, Bryana Burken, Pharmacist and Physician Liaison with Physicians Preference Pharmacy, is joined by Bailie Muñoz, Licensed Esthetician at Hotze Health & Wellness Center, to discuss their compounded Healthy Skin Cream. Bryana and Bailie explain that skin changes can be linked to inflammation, hormonal imbalances, a weakened skin barrier, and other factors. They also discuss why skincare should be personalized and intentional rather than a one-size-fits-all approach.   Bailie breaks down key ingredients in the Healthy Skin Cream and discusses how they help support the skin barrier, calm inflammation, improve moisture retention, reduce redness, promote collagen production, and promote healthier-looking skin. For a skin consultation with Bailie, call 281-698-8770. She can build a skin care regimen (prescription and over the counter) and esthetician treatment plans specializing in Halo, BBL (Broadband Light), Microneedling, Chemical Peels, Dermaplane, HydraFacial, and more. Watch now and subscribe to our podcasts at www.HotzePodcast.com. To receive a FREE copy of Dr. Hotze's best-selling book, “Hormones, Health, and Happiness,” call 281-698-8698 and mention this podcast. Includes free shipping!

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Bilal Siddiqui, MD Long-term management of metastatic castration-sensitive prostate cancer (mCSPC) goes beyond selecting an effective therapy—it also requires careful consideration of tolerability, drug interactions, and treatment access. Balancing these factors can help clinicians personalize care while supporting adherence and quality of life over time. Joining Dr. Charles Turck to share practical strategies for navigating these decisions and tailoring treatment to each patient's unique needs is Dr. Bilal Siddiqui. He's an Assistant Professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston.

Prescription medications, over-the-counter drugs and supplements are incredibly common among older adults, yet many of these routine treatments can unexpectedly impact cognitive function and brain health. To help us safely navigate medication management, Dr. Lauren Welch, a clinical geriatric pharmacy practitioner, joins the podcast to discuss how common drugs affect cognition, the risks of drug-drug interactions, and how families can effectively partner with their health care team to review and de-prescribe medications.  Guest: Lauren Welch, PharmD, BCGP, clinical geriatric pharmacy practitioner, Veterans Affair Geriatrics Research Education and Clinical Center   Show Notes Learn more about the Wisconsin Pharmacy Quality Collaborative (WPQC) and how to get a physician referral at the Pharmacist Society of Wisconsin's website. Learn more about the effect of blood pressure control on dementia risk, mentioned by Dr. Welch at 22:50, by listening to our past episode “SPRINT to a Healthy Mind: How Blood Pressure Control Affects Brain Health and Dementia Risk” on our website.   Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer's. All donations go toward outreach and production. Learn about Dr. Chin's book, When Memory Fades: What to Expect at Every Stage, from Early Signs to Full Support for Alzheimer's and Dementia.

Botulinum toxin products are used across a wide range of therapeutic indications, yet many health systems have not evaluated whether product selection aligns with both clinical evidence and financial stewardship. Matt Groth, Director of Pharmacy and Pharmaceutical Supply Chain Management at the University of Rochester Medical Center, joins Kerry Schwarz to discuss how his team implemented a botulinum toxin stewardship strategy by evaluating evidence, engaging clinicians, and standardizing product selection.   Guest Speaker: Matthew D. Groth, PharmD, MS Director of Pharmacy Pharmaceutical Supply Chain Management University of Rochester Medical Center   Host: Dr. Kerry Schwarz, Pharm.D., MPH Senior Clinical Manager, Evidence-Based Medicine and Outcomes Vizient Center for Pharmacy Practice Excellence    Show Notes:  00:05 Introduction Learn why botulinum toxin stewardship is an emerging opportunity for health systems. Hear how clinical evidence and financial strategy can work together to optimize product selection. 01:25 Reviewing the evidence Explore the evidence supporting available botulinum toxin products, including indications, safety, and dosing considerations. Understand why limited clinical differences between products create opportunities for formulary evaluation. 02:31 Identifying stewardship opportunities Learn how organizations evaluate acquisition costs, reimbursement, payer policies, and contracting opportunities. Discover how financial analysis helps identify opportunities to reduce costs while maintaining quality patient care. 04:29 Implementing a preferred product strategy Hear how provider engagement, financial transparency, and P&T committee support helped drive adoption. Learn how a phased implementation approach increased market share while improving financial performance. 08:11 Lessons learned from implementation Explore the operational considerations that support successful implementation, from inventory management to prior authorizations. Learning why collaboration with physicians, nurses, office staff, and billing teams is essential to long term success. 10:57 Key takeaways Review the core elements of a successful botulinum toxin stewardship strategy. Learn how multidisciplinary collaboration can improve value while maintaining high quality patient care.   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed  

In this podcast episode, Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP, and Anthony Perissinotti, PharmD, BCOP, discuss the role, efficacy, and safety of agents targeting BCMA in the personalized care of patients with multiple myeloma after disease progression on 1 or 2 previous lines of therapy, including: A Brief Overview of BCMA in Multiple Myeloma Advances in BCMA-Targeted Agents in Progressing Myeloma Selection of BCMA-Directed Therapies for Early Relapse MM Operational Challenges Faced by Oncology Pharmacists Regarding the Incorporation of BCMA-Targeted Agents in Practice Identifying and Managing Adverse Events Associated With BCMA-Directed Agents Presenters:  Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP Clinical Oncology Pharmacy Manager Atrium Health Levine Cancer Institute Charlotte, North Carolina Anthony Perissinotti, PharmD, BCOP Hematology Clinical Pharmacist Specialist University of Michigan Ann Arbor, Michigan Link to full program:https://bit.ly/4gCsgXt Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Integrative Care Impact and the Expanding Role of the Pharmacist | TWIRx Today's episode of This Week in Pharmacy explores two major opportunities shaping the future of the profession: the growth of holistic and integrative pharmacy services inside community pharmacies, and the expanding demand for pharmacists across the business, insurance, and PBM sectors. In our first segment, Todd Eury welcomes special guests Robert Kress, RPh, and Dr. Bianca Bradshaw, PharmD, owner of Elmore Pharmacy in Red Bluff, California. Together, they discuss the tremendous opportunity for independent pharmacies to build holistic and integrative health departments that respond to growing consumer demand for natural products, supplements, wellness solutions, and personalized care. Dr. Bianca Bradshaw, PharmD https://www.linkedin.com/in/bianca-bradshaw-141092205/ Patients are increasingly seeking more natural approaches to health, but they still need trusted clinical guidance. Community pharmacists are uniquely positioned to help patients evaluate products, avoid harmful interactions, understand evidence, and develop safer, more effective wellness plans. This conversation explores how pharmacies can create new service lines, improve patient relationships, and establish sustainable revenue opportunities through integrative care. In our second segment, Dr. Bonnie Hui-Callahan, PharmD, returns to the show to discuss career opportunities for pharmacists within Judi Health and Capital Rx, as well as the broader business and insurance side of pharmacy. Dr. Bonnie Hui-Callahan, PharmD https://www.linkedin.com/in/bonnie-hui-callahan/ As PBMs continue to evolve, new-generation models are creating demand for pharmacists who understand clinical care, benefits, formulary strategy, patient access, data, and healthcare economics. Bonnie shares why pharmacists will remain essential as PBMs transform and why the profession should look beyond traditional dispensing and clinical practice roles when considering future career paths. Today's episode is sponsored by Independent Pharmacy Cooperative and SuiteRx. Listen to This Week in Pharmacy on the Pharmacy Podcast Network.

"When we think of drug interactions, specifically, the National Cancer Institute actually defines this as a change in the way a drug acts in the body when taken with certain other drugs, herbals, or foods or when taken with certain medical conditions. Drug interactions may cause the drug to either be more or less effective or cause effects on the body that are not expected," Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about interaction pathways. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD), including 30 minutes of pharmacotherapeutic content, by listening to the full recording and completing an evaluation at courses.ons.org by July 10, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report increased knowledge related to drug interactions in oncology care. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series ONS Voice articles: Are Your Patients Taking Herbs That May Interact With Their Cancer Drugs? Pharmacogenomics Testing Helps to Ensure That Effective Therapy Is Safe Therapy Use of Herbal Products Carries Risk for Drug Interactions, but Patient–Clinician Knowledge, Communication Remain Low What the Research Says About Drug Interactions and Medical Cannabis ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) ONS Huddle Cards: DPYD Gene and DPD Enzyme Pharmacogenomics ONS Oral Anticancer Medication Toolkit American Journal of Nursing articles: Understanding Pharmacokinetics: Part1: Drug Absorption Understanding Pharmacokinetics: Part 2: Drug Distribution Understanding Pharmacokinetics: Part 3: Drug Metabolism Understanding Pharmacokinetics: Part 4: Drug Elimination Journal of Nuclear Medicine Technology articles: Pharmacology, Part 1: Introduction to Pharmacology and Pharmacodynamics Pharmacology, Part 2: Introduction to Pharmacokinetics ClinPGx To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "One of the most notable food interactions that interacts with many different medications is actually grapefruit or grapefruit juice. This is known to be a very strong CYP3A4 inhibitor. … A lot of medications are metabolized through the CYP3A4 pathway. By inhibiting the effect of these enzymes, that can actually increase and significantly increase the concentrations of these therapies. It's not an interaction that's just limited to grapefruit. I would say grapefruit being in the food interaction is kind of one of the most well-known, but it can also be seen with other foods as well, like pomegranate juice or a very specific type of orange called Seville oranges. And this is really just due to the presence of a substance called furanocoumarins." TS 6:12 "There have been a pretty large number of genes identified that are responsible for coding some of those common enzyme families that I had been discussing, some of those CYP450 enzymes, but other enzymes as well that are important for drug metabolism. Based on the type of gene, there could be some different categories where patients are normal metabolizers, intermediate metabolizers, or poor metabolizers. There are some other categories as well based on the type of gene we're looking at. And that can ultimately impact the way you are able to metabolize drugs." TS 15:56 "Another common [geneotypic variation] that we always think about in oncology is G6PD, where if someone has G6PD deficiency, these patients can be at greater risk of hemolytic anemias when receiving certain types of therapies. Dapsone and rasburicase are just a couple that have been associated with this risk." TS 17:50 "One of the big concerns is always polypharmacy. Our patients truly can be on a lot of medications. In the field that I work in, transplant, patients automatically from their transplant are on many, many different medications that can potentially predispose them to side effects. … But I think when it comes to the many drug interactions that may flag in these situations, we really have to look at the patient as a whole. Like, how long have these patients been on these therapies? Are they having side effects? Have they been on the combination for a very long time now? So I think that not just looking at the drug reference and seeing that there are like 10 different interactions flagged, but really assessing your patient as a whole can be very important—just because real-world practice, of course, is not black and white. It's often very gray, so it's just important to use clinical judgment in those scenarios." TS 26:10

Send us Fan MailSchedule an Rx AssessmentAdding telemedicine as a revenue stream...How do you do it? On this episode of the Bottom Line Pharmacy Podcast, we sit down with Mehrdad Hariri, Founder and CEO of RxConnexion, to break down:The real reason most pharmacies struggle to get tractionHow telemedicine actually works inside a pharmacyWhy telemedicine isn't just for compounding And more!Stay connected with Mehrdad Hariri and RxConnexion: Adding telemedicine as a revenue stream...How do you do it? On this episode of the Bottom Line Pharmacy Podcast, we sit down with Mehrdad Hariri, Founder and CEO of RxConnexion, to break down:The real reason most pharmacies struggle to get tractionHow telemedicine actually works inside a pharmacyWhy telemedicine isn't just for compounding And more!Stay connected with Mehrdad Hariri and RxConnexion: RxConnexion Website: https://www.rxconnexion.com/RxConnexion Facebook: https://www.facebook.com/PSGARXRxConnexion Instagram: https://www.instagram.com/rxconnexion/RxConnexion YouTube: https://www.youtube.com/ ⁨@RxConnexion⁩ RxConnexion TikTok: https://www.tiktok.com/@rxconnexionStay connected with us: FacebookTwitterLinkedInScotty Sykes – CPA, CFP LinkedInScotty Sykes – CPA, CFP TwitterBonnie Bond – CPA LinkedInBonnie Bond – CPA TwitterMore resources on this topic: Podcast – Driving Independent Pharmacy Profitability in 2026 with Nicolette Mathey, PharmD, CEO of Atrium24Podcast – 2026 Quarter 2 Pharmacy UpdatePodcast – America 250, The history of Pharmacy, Q&A

In this episode, Sheila Arquette, President & CEO of NASP, speaks with Santana VanDyke, MD, Assistant Professor of Dermatology and Director of the Hidradenitis Suppurativa Clinic at University of Vermont Health, and Ryan Lackey, PharmD, CPPS, Ambulatory Pharmacist Clinician and Co-Director of the clinic. They discuss Hidradenitis Suppurativa (HS), including disease presentation, treatment options, emerging therapies, and research currently underway. The conversation highlights UVM Health's collaborative care model that brings together dermatology and specialty pharmacy to improve the patient experience and clinical outcomes.  

GLP-1 therapies are transforming pharmacy benefits, and Express Scripts is leading the way. Harold Carter, PharmD, SVP of Trade Relations, joins host Eric Glazer to discuss how one of the nation's largest PBMs is navigating this disruptive moment in healthcare. Harold shares how Express Scripts is: Capping costs of GLP-1 therapies to expand patient access while keeping plan spending predictable. Redesigning funding models to strike a balance between affordability, predictability, and outcomes. Leveraging digital tools and AI to reduce friction in the member experience and support long-term adherence. Rethinking formularies not just as cost-control tools but as part of a broader population health and behavioral change ecosystem. You'll also hear his forward-looking perspective on how PBMs will evolve over the next three to five years, and the key questions health plans and employers should be asking today to prepare for the future of pharmacy benefits. About Dr. Harold Carter:   Harold Carter, PharmD, is responsible for leading all interactions and contracting with pharmaceutical manufacturers and oversees strategy and management of Express Scripts' drug formularies, data & insights, client underwriting, and product strategy and development. In his nearly 14 years with the organization, Harold has held numerous leadership roles oriented around critical efforts to lower the cost of prescription drugs and ensuring medication access for Express Scripts clients and members. Harold's previous responsibilities include oversight of the organization's medical pharma contracting and drug procurement teams, as well as leading the strategy, development and execution of Express Scripts' wholesale market, value-based solutions and generic strategy, and development of Express Scripts' advanced utilization management solutions.  In addition to his work at Express Scripts, Harold serves on numerous boards including LifeWise Stl Board of Directors, St. Louis University High School Board of Trustees and IVI Board of Directors. Harold earned his doctorate in pharmacy from St. Louis College of Pharmacy.   Partner with Bright Spots Ventures: If you are interested in speaking with the Bright Spots Ventures team to brainstorm how we can help you grow your business via content and relationships, email hkrish@brightspotsventures.com  About Bright Spots Ventures: Bright Spots Ventures is a healthcare strategy and engagement company that creates content, communities, and connections to accelerate innovation. We help healthcare leaders discover what's working, and how to scale it. By bringing together health plan, hospital, and solution leaders, we facilitate the exchange of ideas that lead to measurable impact. Through our podcast, executive councils, private events, and go-to-market strategy work, we surface and amplify the "bright spots" in healthcare, proven innovations others can learn from and replicate. At our core, we exist to create trusted relationships that make real progress possible. Visit our website at www.brightspotsinhealthcare.com.  

Host Nick Dorich talks with Scott D. Pope, PharmD, CEO and founder of CareerScript, about his framework distinguishing "patient" from "consumer" mindsets in healthcare, how patients arrive underinformed, and hyper-informed consumers spending their own money demand more. They discuss how real-world friction can turn pharmacists into perceived gatekeepers, and the need for pharmacies to self-assess and shift toward consumer-valued advisory care. Pope also takes time to explain how individual pharmacists need better career-navigation tools than generic personality tests and the gap CareerScript fills. https://www.careerscript.com

Deprescribing is an important component of patient care as medication regimens are reassessed to ensure ongoing appropriateness, safety, and alignment with patient goals. This course reviews key deprescribing principles, including when it may be appropriate to discontinue therapy and important considerations for patient monitoring and follow-up. You will be better prepared to support evidence-based deprescribing decisions and collaborate with patients and providers to optimize medication use. HOSTRachel Maynard, PharmDGameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTKristin S. Meyer, PharmD, BCGP, FASCPProfessor of Pharmacy Practice,Drake University College of Pharmacy and Health Sciences Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Discuss key principles and clinical considerations for deprescribing.2. Compare patient-specific factors that influence evidence-based deprescribing decisions, including risks, benefits, and treatment goals.Rachel Maynard and Kristin Meyer have no relevant financial relationships to disclose.0.075 CEU/0.75 HrUAN: 0107-0000-26-249-H01-PInitial release date: 7/6/2026Expiration date: 7/6/2029Additional CPE details can be found here.

Deprescribing is an important component of patient care as medication regimens are reassessed to ensure ongoing appropriateness, safety, and alignment with patient goals. This course reviews key deprescribing principles, including when it may be appropriate to discontinue therapy and important considerations for patient monitoring and follow-up. You will be better prepared to support evidence-based deprescribing decisions and collaborate with patients and providers to optimize medication use.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTKristin S. Meyer, PharmD, BCGP, FASCPProfessor of Pharmacy Practice,Drake University College of Pharmacy and Health SciencesGET CE FOR LISTENING!Stay Compliant. Grow Clinically. Practice with Confidence. Pharmacist CE Subscription: All your CE in one convenient subscription.All episodes, CE, and Practice Resources for the GameChangers Clinical Update is included with your Pharmacist CE Subscription. But wait…there's even more!The Pharmacist CE Subscription includes: -  Compliance and licensure CE -  GameChangers Clinical Updates-  Practical continuing education across patient care topics *The subscription does not include microcredentials or certificates, which are available separately for pharmacists seeking specialized service training. Purchase Now!PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the Pharmacist CE Subscription. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Pharmacist CE Subscription and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Discuss key principles and clinical considerations for deprescribing.2. Compare patient-specific factors that influence evidence-based deprescribing decisions, including risks, benefits, and treatment goals.Rachel Maynard and Kristin Meyer have no relevant financial relationships to disclose.0.075 CEU/0.75 HrUAN: 0107-0000-26-249-H01-PInitial release date: 7/6/2026Expiration date: 7/6/2029Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Interview with Willie Eggleston, PharmD

To open the episode, Erica Marini, PharmD, discussed a roundup of FDA and research updates in neurology. She covered the shifting accelerated-approval pathway for AMT-130 (uniQure), a gene therapy for Huntington disease, and a similar back-and-forth for a Hunter syndrome gene therapy. She also noted an expanded indication for olezarsen (Tryngolza; Ionis Pharmaceuticals) in severe hypertriglyceridemia, a UK study linking hypotension to Alzheimer risk, and data suggesting shingles vaccination may lower dementia risk in Medicare beneficiaries. From the American Headache Society meeting, she highlighted phase 2b data on the TRPM8 agonist elismotrep (Kallyope), and the anti-PACAP antibody bocunebart (Lundbeck) for migraine, along with retrospective findings tying CGRP monoclonal antibodies to increased fracture risk and higher odds of spontaneous abortion in early pregnancy.The core interview featured Adrian Wong, PharmD, MPH, BCCCP; and Cayley Krkljes, PharmD, BCPS, of Beth Israel Deaconess Medical Center who discussed a systematic review published in Pharmacotherapy of clinically significant drug-drug interactions with phenobarbital and primidone. Wong and Krkljes described growing use of phenobarbital for alcohol withdrawal and note that health care professionals often underappreciate its interaction potential despite it being a well-known enzyme inducer. Key findings included an induction onset of 24 hours to 30 days and an offset of 2 to 8 weeks, findings that carry particular weight for transitions of care since inpatient dosing effects can persist well after discharge. The most clinically impactful interactions involved anticoagulants (warfarin and direct oral anticoagulants [DOACs]), methadone, and immunosuppressants, with approximately 85% of reviewed studies reporting some outcome impact. They also pushed back on recent social media claims that phenobarbital-DOAC interactions are not clinically relevant, pointing out methodological limitations in the studies behind that claim.The conversation moved into practical risk stratification: The guests described considering a patient's individual risk factors—such as recent thrombosis, transplant status, or opioid use disorder treatment with methadone or buprenorphine—before choosing phenobarbital over benzodiazepines for alcohol withdrawal. They outlined next steps for research, including studying real-world outcomes in high-risk medication combinations and surveying health care professional awareness of these interactions to identify education gaps. The episode closed with career advice for pharmacists interested in research—start small, find mentors, and leverage institutional resources.Key Takeaways: Phenobarbital's interaction risk is widely underrecognized. Despite growing use for alcohol withdrawal, phenobarbital's enzyme-inducing effects can persist for weeks after the last dose (onset 24 hours to 30 days; offset 2 to 8 weeks), making transitions of care a critical window for catching interactions—especially with anticoagulants, methadone, and immunosuppressants, which accounted for the most clinically impactful outcomes in the review. Not all "reassuring" data holds up under scrutiny. Wong and Krkljes challenged circulating social media claims that phenobarbital-DOAC interactions aren't clinically relevant, noting the studies behind those claims had methodological limitations, emphasizing the importance of evaluating primary literature rather than secondhand interpretations. Risk stratification should guide phenobarbital use. Individual patient factors (eg, recent thrombosis, transplant status, or opioid use disorder treatment with methadone or buprenorphine) should inform whether phenobarbital or a benzodiazepine is the safer choice for alcohol withdrawal management.

How Targeted Therapies Are Reshaping Treatment for Platinum-Resistant Ovarian Cancer Platinum-resistant ovarian cancer remains one of the most challenging settings in oncology, with limited treatment options and historically poor outcomes for many patients. On this episode of Unscripted, the AMCP Podcast, guest host Abby Kim, PharmD, BCOP, Senior Director of Clinical Strategy and Oncology Specialty Solutions at Prime Therapeutics, sits down with Kathleen Moore, MD, Deputy Director of the Fred & Pamela Buffett Cancer Center and Professor of Obstetrics and Gynecology at Nebraska Medicine, to discuss the evolving treatment landscape for recurrent ovarian cancer and the growing role of biomarker-driven care. Dr. Moore explores the history and challenges of treating platinum-resistant disease, reviews the clinical evidence behind ELAHERE®, examines the importance of folate receptor alpha testing, and shares insights on treatment sequencing, patient-reported outcomes, safety and tolerability considerations, and emerging therapies that may further expand options for patients and inform decision-making across managed care. Sponsored by Abbvie, Inc. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

What does it take to build a healthcare business that has served guests for 25 years? In this special episode, Bryana Burken, Pharmacist and Physician Liaison with Physicians Preference Pharmacy, shares the story behind the pharmacy's journey, the lessons learned along the way, and the principles that continue to guide its mission today. Bryana discusses how Physicians Preference Pharmacy began in 2001 with a focus on helping guests achieve more consistent results from hormone therapy through quality, precision, and individualized care. She explains the pharmacy's commitment to personalized medicine, the importance of the patient-provider-pharmacist relationship, and the extensive quality control measures used to ensure compounded medications meet strict standards. The episode also highlights the pharmacy's growth beyond bioidentical hormones into areas such as immune support, longevity, skincare, thyroid health, and other customized therapies. Bryana shares why personalized healthcare, exceptional guest service, and a commitment to addressing root causes rather than simply managing symptoms remain central to the pharmacy's mission. Most importantly, she reflects on the guests, practitioners, and families who have made the past 25 years possible and looks ahead to the future of personalized wellness. Visit www.house.gov and enter your zip code to find your U.S. Representative. CALL the Capitol Switchboard at 202-224-3121 and ask to be connected to your Representative to ask them to support H.R. 8630, the Protecting Equal Access to Thyroid Act of 2026. Watch now and subscribe to our podcasts at www.HotzePodcast.com. To learn more about Physicians Preference Pharmacy, please visit https://physicianspreferencerx.com/ To receive a FREE copy of Dr. Hotze's best-selling book, Hormones, Health, and Happiness, call 281-698-8698 and mention this podcast. Includes free shipping!

Host: Alexandria May, PharmD, BCPS Guest: Neil M. Iyengar, MD As first-line treatment options for metastatic triple-negative breast cancer continue to expand, emerging evidence and guideline updates are reshaping treatment selection. In this expert-led discussion, Dr. Alexandria May and Dr. Neil Iyengar review the growing role of biomarker-driven decision-making and examine how data from ASCENT-03, ASCENT-04, and TROPION-Breast02 are influencing preferred treatment approaches. Dr. Iyengar is the Director of the Cancer Survivorship Program and Co-Director of the Breast Medical Oncology Program at Winship Cancer Institute at Emory University.

Functional medicine has been on the tip of the tongue and observed online and on social media for years now, more than in the past, but just what is it and how can it help our patients in pain? Dr. Lauren Castle joins us as a dual expert in the realm of functional medicine and psychedelic pharmacy to clear the fog and address any myths out there for all things functional medicine. Come one, come all, to the Pain Pod!!! P.S. Want to contribute or hear about a pain pearl of your own? Message Pain Guy on www.painguy.us or LinkedIn to directly reach Mark and have your voice heard! Guest Info Lauren Castle, PharmD, MS, AFMC Functional Medicine Pharmacists Alliance, Founder (https://www.fmpha.org/) Psychedelic Pharmacists Association, Founder (https://psychedelicpharmacist.org/)

Get the FREE GUIDE to 10 Nonclinical Careers at nonclinicalphysicians.com/freeguide. Get a list of 70 nontraditional jobs at nonclinicalphysicians.com/70jobs.                                                                                                 =============== In this 2022 replay, Dr. Frieda Wiley, a PharmD and freelance medical writer, talks about her path into medical writing, the realities of remote pharmacy work, and the book she wrote after struggling with the isolation that came with it. Her background spans community pharmacy, medication therapy management, and a fully remote role she took on for a managed care firm. One that started as an attractive, flexible opportunity and gradually became a rigid 8-to-5 schedule with mandatory overtime. She walks through how her writing career developed alongside her clinical work, from supporting a medical writing team during a pharmacy school rotation to freelancing for patient education publications. And she highlights the specific isolation, depression, and physical symptoms she experienced as a fully remote worker, which became the basis for her book, Telecommuting Psychosis: From Surviving to Thriving While Working in Your Pajama Pants. She also shares the questions she now recommends asking before accepting any remote role. You'll find links mentioned in the episode at nonclinicalphysicians.com/avoid-psychosis-working-remotely/.

As health systems grow more complex and executive expectations continue to expand, organizations must develop the next generation of pharmacy leaders. Host Carolyn Liptak is joined by Dr. Bonnie Levin and Dr. Cedric Terrell to discuss the growing pharmacy leadership pipeline challenge, the skills today's leaders need to succeed, and practical ways to identify and develop the next generation of pharmacy executives.   Guests:  Bonnie Levin, PharmD, MBA, FASHP VP, Pharmacy Services Medstar Health Cedric Terrell, PharmD, MHA SVP & Chief Pharmacy Officer  Pharmacy Enterprise Services CommonSpirit Health   Host:   Carolyn Liptak, MBA, BS Pharm Pharmacy Executive Director, Regulatory Compliance Vizient Center for Pharmacy Practice Excellence     Show Notes: 00:54 - The Pharmacy Leadership Pipeline Why healthsystems are facing a shortage of pharmacy leaders. The impact of retirements, workforce changes, and succession planning challenges. How evolving expectations are reshaping leadership roles as pharmacy creates "a table that others want to sit at." 02:21 - The Modern Pharmacy Executive How pharmacy leadership has changed over the last several years. Why leaders now oversee larger, more complex healthcare enterprises. Why today's leaders must think like pharmacy business executives, not just department directors. 03:31 - Skills Every Future Leader Needs The growing importance of financial stewardship and business acumen. Why strategic thinking is just as valuable as clinical expertise. How pharmacy leaders create value through operations, finance, and innovation. 04:46 - Identifying Emerging Leaders What makes an informal leader stand out, from raising their hand to offering solutions instead of problems. Why leadership is a behavior, not a position. The importance of mentoring future leaders and exposing them to experiences beyond their own department. 06:06 - Preparing the Next Generation Where pharmacy education and leadership development are falling short. Why financial literacy, budgeting, and operational knowledge are essential leadership skills. How early exposure to business decisions helps future leaders build confidence. 07:31 - Residency and Real World Experience The value residency programs provide in developing clinical expertise. Why practical business experience is equally important for future executives. How mentorship and cross functional learning prepare pharmacists for broader leadership roles. 09:16 - Moving Into Executive Leadership How clinically trained pharmacists can expand into enterprise leadership. Bonnie shares why saying yes to leading behavioral health became one of the most valuable experiences of her career. Why leaders should seek opportunities that stretch their skills beyond pharmacy. 11:03 - Career Growth Through Opportunity Why saying yes to unfamiliar challenges accelerates leadership development. Expanding experience into areas like ambulatory care, payer strategy, imaging, and laboratory services. Cedric explains why creating opportunities is more valuable than waiting for them to appear. 12:07 - Leadership Advice Bonnie shares the quote that shaped her leadership philosophy. Cedric reflects on advice from his mentor to prepare today for the role you want three to five years from now. Why successful leaders stay curious and become comfortable making decisions with uncertainty. 13:58 - Looking Ahead Why today's pharmacy leaders are optimistic about the future. The value of innovation, persistence, collaboration, and strong professional relationships. Final reflections on building the next generation of pharmacy executives through mentorship, curiosity, and continuous learning.   Subscribe Today!  Apple Podcasts  Spotify  YouTube  RSS Feed   

Propofol remains a cornerstone sedative for mechanically ventilated critically ill patients and is supported by PADIS guidelines and favored for its rapid onset, titratability, and limited side effects. However, its use in hemodynamically unstable patients remains a persistent clinical dilemma. In this episode of the Society of Critical Care Medicine (SCCM) Podcast, host Kyle Enfield, MD, is joined by Scott Benken, PharmD, MHPE, BCCCP, and Nathan Smischney, MD, MS, to explore the risks, benefits, and evolving evidence surrounding propofol use in this high-risk population.     The discussion examines the physiologic basis of propofol-associated hypotension and how that can manifest in different patients, such as those with sepsis and septic shock. Patient selection and real-time assessment of hemodynamic trends are essential. Additional considerations include the recognition of and monitoring for propofol infusion syndrome, a rare but life-threatening complication.     The episode also explores alternative drugs such as dexmedetomidine and ketamine, highlighting the benefits and risks of each. Emerging strategies are discussed, including a ketamine-propofol combination called ketafol and its utility in balancing sedation and hemodynamic stability.  Listeners will gain expert insights into propofol use in the ICU and a deeper understanding of patient-centered approaches to sedation.    Resources referenced in this episode:   Lewis K, Balas MC, Stollings JL, et al. A focused update to the clinical practice guidelines for the prevention and management of pain, anxiety, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2025;53(3):e711-e727.  Russotto V, Myatra SN, Laffey JG, et al. Intubation practices and adverse peri-intubation events in critically ill patients from 29 countries. JAMA. 2021;325(12):1164-1172.  Boncyk C, Devlin JW, Faisal H, et al. INhaled Sedation versus Propofol in REspiratory failure in the Intensive Care Unit (INSPiRE-ICU1): protocol for a randomised, controlled trial. BMJ Open. 2024;14(10):e086946.  O'Gara B, Serra AL, Englert JA, et al. Inhaled sedation versus propofol in respiratory failure in the ICU (INSPiRE-ICU2): study protocol for a multicenter randomized controlled trial. Trials. 2025;26(1):114. 

Send us Fan MailSend us Fan MailSchedule an Rx AssessmentWelcome to another episode of the Bottom Line Catch Up and the team is back together celebrating America 250!In this episode, we break down:Tradeshow seasonMFP refunds and taxesHow to find a pharmacy buyerAnd more!Stay connected with us: FacebookTwitterLinkedInScotty Sykes – CPA, CFP LinkedInScotty Sykes – CPA, CFP TwitterBonnie Bond – CPA LinkedInBonnie Bond – CPA Twitter More resources on this topic: Podcast - The Bottom Line Catch Up | Ep. 1 | Tax Season, Transitions, and the Peptide WavePodcast – Driving Independent Pharmacy Profitability in 2026 with Nicolette Mathey, PharmD, CEO of Atrium24Podcast – 2026 Quarter 2 Pharmacy Update

Functional medicine has been on the tip of the tongue and observed online and on social media for years now, more than in the past, but just what is it and how can it help our patients in pain? Dr. Lauren Castle joins us as a dual expert in the realm of functional medicine and psychedelic pharmacy to clear the fog and address any myths out there for all things functional medicine. Come one, come all, to the Pain Pod!!! P.S. Want to contribute or hear about a pain pearl of your own? Message Pain Guy on www.painguy.us or LinkedIn to directly reach Mark and have your voice heard! Guest Info Lauren Castle, PharmD, MS, AFMC Functional Medicine Pharmacists Alliance, Founder (https://www.fmpha.org/) Psychedelic Pharmacists Association, Founder (https://psychedelicpharmacist.org/)

Beta-blockers have long been considered a foundational therapy following myocardial infarction, yet emerging data are challenging their routine use in all patients. This course discusses recent evidence on outcomes associated with beta-blocker therapy after MI, particularly in patients without reduced ejection fraction, and explores the ongoing debate over the benefits, risks, and duration of therapy. You will gain practical insight to support evidence-based decision-making and individualized pharmacotherapy recommendations in post-MI care. HOSTRachel Maynard, PharmDGameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTAnna Crider, PharmD, BCCPClinical Pharmacy Specialist,Emory University HospitalTaylor Merritt, PharmDPGY2 Internal Medicine Pharmacy Resident, Chief Pharmacy Resident,Emory University Hospital Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Summarize contemporary evidence regarding beta-blocker therapy after myocardial infarction.2. Describe clinical considerations that may influence the decision to initiate, continue, or deprescribe beta-blocker therapy following myocardial infarction.Rachel Maynard, Anna Crider, and Taylor Merritt have no relevant financial relationships to disclose.0.075 CEU/0.75 HrUAN: 0107-0000-26-242-H01-P Initial release date: 6/29/2026Expiration date: 6/29/2027Additional CPE details can be found here.

Beta-blockers have long been considered a foundational therapy following myocardial infarction, yet emerging data are challenging their routine use in all patients. This course discusses recent evidence on outcomes associated with beta-blocker therapy after MI, particularly in patients without reduced ejection fraction, and explores the ongoing debate over the benefits, risks, and duration of therapy. You will gain practical insight to support evidence-based decision-making and individualized pharmacotherapy recommendations in post-MI care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTSAnna Crider, PharmD, BCCPClinical Pharmacy Specialist,Emory University HospitalTaylor Merritt, PharmDPGY2 Internal Medicine Pharmacy Resident, Chief Pharmacy Resident,Emory University HospitalGET CE FOR LISTENING!Stay Compliant. Grow Clinically. Practice with Confidence. Pharmacist CE Subscription: All your CE in one convenient subscription.All episodes, CE, and Practice Resources for the GameChangers Clinical Update is included with your Pharmacist CE Subscription. But wait…there's even more!The Pharmacist CE Subscription includes: -  Compliance and licensure CE -  GameChangers Clinical Updates-  Practical continuing education across patient care topics *The subscription does not include microcredentials or certificates, which are available separately for pharmacists seeking specialized service training. Purchase Now!PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the Pharmacist CE Subscription. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Pharmacist CE Subscription and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Summarize contemporary evidence regarding beta-blocker therapy after myocardial infarction.2. Describe clinical considerations that may influence the decision to initiate, continue, or deprescribe beta-blocker therapy following myocardial infarction.Rachel Maynard, Anna Crider, and Taylor Merritt have no relevant financial relationships to disclose.0.075 CEU/0.75 HrUAN: 0107-0000-26-242-H01-P Initial release date: 6/29/2026Expiration date: 6/29/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

In this episode, Dr Tsen Vei Lim talks to Drs Grant Comstock and Ryan Feldman. Grant is an Assistant Professor at the Medical College of Wisconsin and Associate Medical Director of the Wisconsin Poison Center and Ryan is a clinical toxicologist, emergency medicine pharmacist, and Clinical Associate Professor at the Medical College of Wisconsin. The interview covers Grant and Ryan's article examining the association between state-level kratom regulations and poison center-reported severe medical outcomes and healthcare use in the United States (US). What is kratom? [01:14]Why people are worried about kratom use in the US [02:58]Grant and Ryan's research question and focus of the study [05:33]The key findings of the study [10:25]The relationship between kratom regulations and kratom-related hospitalisations [12:16]The implications of the findings for existing kratom regulations [13:04]The data that researchers should collect to improve the data vacuum on kratom [18:03]The takeaway from the study: read the discussion! [19:40]About Tsen Vei Lim: Tsen Vei is an academic fellow supported by the Society for the Study of Addiction, currently based at the Department of Psychiatry at the University of Cambridge. His research integrates computational modelling, experimental psychology, and neuroimaging to understand the neuropsychological basis of addictive behaviours. He holds a PhD in Psychiatry from the University of Cambridge (UK) and a BSc in Psychology from the University of Bath (UK). About Grant Comstock: Grant, MD, is an Assistant Professor of Emergency Medicine at the Medical College of Wisconsin and Associate Medical Director of the Wisconsin Poison Center, US. He is board certified in emergency medicine, medical toxicology, and addiction medicine. His academic interests include novel psychoactive substances, harm reduction strategies, and overdose epidemiology. In addition to his clinical work, Dr. Comstock is actively involved in research, medical education, and mentorship within emergency medicine and medical toxicology.About Ryan Feldman: Ryan, PharmD, DABAT, FAACT, is a clinical toxicologist, emergency medicine pharmacist, and Clinical Associate Professor at the Medical College of Wisconsin. He works with the Wisconsin Poison Center, where he helps manage poisoning and overdose cases, and is Toxicology Section Editor for the American Journal of Emergency Medicine. His work focuses on emerging substances, poison center data, overdose trends, and public health responses to toxic exposures. Ryan has published on substances including kratom, phenibut, tianeptine, cannabinoids, and mushroom toxins. He also hosts The Poison Lab, an educational podcast exploring toxicology, outbreaks, and poisoning science.Original article: Association between state-level kratom regulations and poison center-reported severe medical outcomes and healthcare use: A United States national analysis https://doi.org/10.1111/add.70416 The opinions expressed in this podcast reflect the views of the host and interviewees and do not necessarily represent the opinions or official positions of the SSA or Addiction journal.The SSA does not endorse or guarantee the accuracy of the information in external sources or links and accepts no responsibility or liability for any consequences arising from the use of such information.Music provided by Jack Shakespeare. Hosted on Acast. See acast.com/privacy for more information.

Women are driving innovation, improving patient care and leading independent pharmacies through a changing healthcare landscape. In this episode, hosts Jason Callori, Michelle Britt (SVP, Retail Independent, Inside Sales & First Vet Services), and Chelsie Waite (Director of Sales, Retail Independent Sales - West Region) sit down with two remarkable women leaders: Monica Nikseresht, PharmD, and Melissa Hood-Benges, PharmD.   Monica and Melissa share their personal journeys, leadership lessons and insight into key challenges and opportunities. Listen to a conversation highlighting leadership, resilience, advocacy, and innovation, while celebrating women as leaders and change-makers in pharmacy.

In this episode of The ASHE Podcast, hosts Dr. Gonzalo Bearman and Dr. Priya Nori speak with Elizabeth Hirsch, PharmD and David Mott, PhD about their national survey of infectious diseases and antimicrobial stewardship pharmacists in the United States. They discuss the workforce's diverse responsibilities, training and resource challenges, and key findings that have implications for workforce development, retention, and the future of antimicrobial stewardship programs.   Read the full article: Hirsch EB, Mott DA, Gilson AM, et al. A national survey of the infectious diseases and antimicrobial stewardship pharmacist workforce in the United States: work settings, characteristics, employment activities, resources and needs. Antimicrobial Stewardship & Healthcare Epidemiology. 2026;6(1):e76. doi:10.1017/ash.2026.10312

Tarah Davis, PharmD, AFMC, joins Over the Counter to discuss her experience as a functional medicine pharmacist and how she addresses gut health to help patients manage the root causes of their disease states.

What happens when Estrogen and alcohol mix? In this episode we explore how alcohol affects estrogen levels and what every woman should know about drinking during different stages of life.   https://pubmed.ncbi.nlm.nih.gov/10397281/ https://www.mariongluckclinic.com/blog/hormones-and-alcohol-could-reducing-alcohol-help-with-hormone-balancing.html https://news.weill.cornell.edu/news/2024/12/preclinical-study-finds-surges-in-estrogen-promote-binge-drinking-in-females  

For the final episode of The Women's Health Wellness Edit, we sit down with functional medicine expert Dr. John Kim, PharmD, FAARFM to explore why so many people still struggle with brain fog, fatigue, and chronic symptoms despite being "healthy." We dive into the Cell Danger Response, how trauma and chronic stress can impact cellular resilience, and why healing often requires more than diet, supplements, and biohacks. Dr. Kim also walks us through his ENCORE Method for helping the body move out of defense mode and back into healing. This episode is an in-depth and actionable look at how to take control of your body back. Keep in touch with Dr. Kim: https://www.drjohnkim.com https://www.instagram.com/john.pharmd/?hl=en Attend Dr. Kim's upcoming webinar: https://beyonddetox.drjohnkim.com If this episode spoke to you, subscribe and leave a review on your favorite podcast platform or share it with a friend! podcasts.apple.com/us/podcast/slig…od/id1542525641 Follow us on Instagram: www.instagram.com/slightlyspiritualpod/ Follow Cindy on Instagram: www.instagram.com/revealingsoul/ Follow Ali on Instagram: www.instagram.com/alitmoresco/

About this episode:   Data from 2025 shows that over 300,000 children are living in foster care in the United States. The Administration for Children and Families—the federal agency that oversees child welfare programs—aims to keep more children out of the system and with their families. In this episode: a conversation with Assistant Secretary Alex Adams about recent changes to grants and policies that seek to support families affected by substance use and reform practices around survivor benefits for children who have lost their parents.  Guest:  Alex Adams, PharmD, MPH, is the Assistant Secretary for Family Support, leading the Administration for Children and Families. Host:  Dr. Josh Sharfstein is distinguished professor of the practice in Health Policy and Management, a pediatrician, and former secretary of Maryland's Health Department. He served as the Baltimore City Commissioner of Health from 2005 to 2009.  Show links and related content:  Rolling Out the Welcome Mat for Prevention—The Imprint Former Idaho official ended state taking foster kid's Social Security money. Are other states next?—Idaho Capital Sun A Home for Every Child—Administration for Children and Families The AFCARS Dashboard—Administration for Children and Families Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌PublicHealthPod on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Sexually transmitted infection (STI) management continues to evolve, with new treatment options, prevention strategies, and practice considerations that are important for pharmacists to understand. This course reviews recent updates in STI care, including newly approved oral therapies for gonorrhea and doxycycline post-exposure prophylaxis. You will be better prepared to recognize practice-relevant changes and support evidence-based STI prevention, treatment, and patient counseling. HOSTRachel Maynard, PharmDGameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTFrancisco Franco, PharmD, MS, AAHIVPRegistered Store Manager,Walgreens Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe recent updates in STI treatment and prevention that are relevant to pharmacy practice.2. Compare emerging strategies for managing gonorrhea and STI post-exposure prophylaxis.Rachel Maynard and Francisco Franco have no relevant financial relationships to disclose.0.075 CEU/0.75 HrUAN: 0107-0000-26-241-H01-P Initial release date: 6/22/2026Expiration date: 6/22/2027Additional CPE details can be found here.

Sexually transmitted infection (STI) management continues to evolve, with new treatment options, prevention strategies, and practice considerations that are important for pharmacists to understand. This course reviews recent updates in STI care, including newly approved oral therapies for gonorrhea and doxycycline post-exposure prophylaxis. You will be better prepared to recognize practice-relevant changes and support evidence-based STI prevention, treatment, and patient counseling.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpactGUESTFrancisco Franco, PharmD, MS, AAHIVPRegistered Store Manager,WalgreensGET CE FOR LISTENING!Stay Compliant. Grow Clinically. Practice with Confidence. Pharmacist CE Subscription: All your CE in one convenient subscription.All episodes, CE, and Practice Resources for the GameChangers Clinical Update is included with your Pharmacist CE Subscription. But wait…there's even more!The Pharmacist CE Subscription includes: -  Compliance and licensure CE -  GameChangers Clinical Updates-  Practical continuing education across patient care topics *The subscription does not include microcredentials or certificates, which are available separately for pharmacists seeking specialized service training. Purchase Now!PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the Pharmacist CE Subscription. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Pharmacist CE Subscription and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe recent updates in STI treatment and prevention that are relevant to pharmacy practice.2. Compare emerging strategies for managing gonorrhea and STI post-exposure prophylaxis.Rachel Maynard and Francisco Franco have no relevant financial relationships to disclose.0.075 CEU/0.75 HrUAN: 0107-0000-26-241-H01-P Initial release date: 6/22/2026Expiration date: 6/22/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Frontline treatment selection for newly diagnosed multiple myeloma (NDMM) is more complex than ever. With quadruplet regimens and anti-CD38 antibodies redefining the landscape, how do you choose the right therapy for each unique patient? In this exclusive preview, Ashley Chen, PharmD, BCOP (Fred Hutchinson Cancer Center), shares actionable insights on:

Awakening the Future: How Emerging Narcolepsy Type 1 Therapies Are Redefining Care and Expectations On this episode guest host Steve Kheloussi, PharmD, MBA, FAMCP, principal consultant at Kheloussi Consulting, speaks with Amy Lugo, PharmD, BCPS, BC-ADM, FAPhA, FAMCP, founder and CEO of LoneStar Health Solutions, about the evolving treatment landscape for narcolepsy. The discussion explores the burden of delayed diagnosis, the real-world impact of excessive daytime sleepiness and cataplexy, and how treatment may shift from symptom management toward addressing the underlying disease process. Steve and Amy also examine formulary considerations, patient-reported outcomes, utilization management challenges, and how managed care organizations can balance access, value, and patient-centered care as new therapies enter the market. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Send us Fan MailSchedule an Rx AssessmentAre you looking at getting into a central fill model? This episode is for you. On this episode of the Bottom Line Pharmacy Podcast, Scotty Sykes, CPA, CFP® and Austin Murray sit down with Oliver Hoopes, Owner of Cache Valley Pharmacy to break down: The supplement revenue gap between pharmacies and hormone clinics Why every independent pharmacy should be a hormone clinic How central fill models work and how to get startedAnd more!Stay connected with Oliver and Cache Valley Pharmacy: Cache Valley Pharmacy WebsiteCache Valley Pharmacy FacebookCache Valley Pharmacy InstagramMontana Family PharmaciesFocus PharmacologyStay connected with us: FacebookTwitterLinkedInScotty Sykes – CPA, CFP LinkedInScotty Sykes – CPA, CFP TwitterBonnie Bond – CPA LinkedInBonnie Bond – CPA Twitter More resources on this topic: Podcast – Driving Independent Pharmacy Profitability in 2026 with Nicolette Mathey, PharmD, CEO of Atrium24Podcast – 2026 Quarter 2 Pharmacy UpdatePodcast – Building a Super Culture in Your Pharmacy

Only roughly 50% of new GLP-1 prescriptions were getting approved for coverage in 2023. From a plan sponsor's seat, that looks like pharmacy trend spiking 9%, 12%, even 20% year over year. From a pharma manufacturer's seat, it's half their prescriptions not getting filled. Same market, opposite problems — and that's exactly the lens this episode flips on. In this episode, Stacey Richter speaks with Ophelia Johnson, who built new business channels for a pharmaceutical manufacturer that created the GLP-1 boom and has since launched a consulting practice at e-fi.works, about how cash pay models work from the inside — coupon platforms, telehealth channels, white label pharmacy models, and employer carve-outs — and where the new fees are hiding. WHAT YOU'LL LEARN ✅ How the Inflation Reduction Act, PBM legal scrutiny, drug shortages, and the compounding bypass converged with ~50% GLP-1 prior auth denial rates in 2023 to push pharma into building cash pay channels that cut the PBM out entirely ✅ How the savings coupon model works: manufacturer buys the patient down to a flat transparent cash price via platforms like GoodRx, pays a fixed per-script fee instead of a PBM rebate, and the coupon platform makes the pharmacy whole — transparent math, no black box ✅ How the telehealth channel and white label pharmacy models extend the distribution chain beyond retail — and why shipping costs, credit card fees, dispensing fees, and new supply chain partners create gross-to-net and revenue leakage risk for manufacturers not built for it ✅ Why "direct to employer" is a misnomer: PBM contracts prohibit pharma from selling directly to self-insured employers, so third-party transparent administrators have emerged — but plan sponsors need to run the math first, given ERISA complications and PBM contract leverage ✅ How PBMs are now charging fees for hub-like patient support services to manage the exact prior auth complexity they created — a Whack-a-Mole shift of profitability that everyone needs to map before signing anything ✅ Ophelia's three-part practical advice: map the full patient journey and all ecosystem player incentives before building any new model (pharma); treat affordability as a clinical risk factor (clinicians); demand auditable medication abandonment data rather than settling for rebate yield metrics (plan sponsors) WHY THIS MATTERS If collaboration is the next innovation, everyone has to understand the incentives of every player in the ecosystem — not just their own. The same 50% of unfilled GLP-1 prescriptions that looks like runaway pharmacy trend from a plan sponsor's seat looks, from a manufacturer's seat, like half their market going dark — and both sides are making moves that affect each other. Understanding those moves, where fees are being layered on, and when fair profit tips into what Stacey calls profiteering is what this episode maps. TUNE IN NEXT WEEK Next week is the 401-level companion to this one — Stacey goes solo on the PBM and GPO contracting mechanics behind why cash pay became a thing, and why cheaper or better drugs can inexplicably end up off formulary or buried under prior auth. === LINKS ===

What happens when learners teach learners? Layered learning is a teaching model that brings pharmacy students, residents, and preceptors together in a collaborative learning environment. Our host Carolyn Liptak is joined by Dr. Sarah Eggers Russell, PharmD, BCACP, CPP of UNC Health REX and Dr. Kimberly James, PharmD of UF Health to discuss how layered learning works in pharmacy residency programs and why it continues to gain traction across healthcare settings. They share perspectives from their own programs and discuss what it takes to create meaningful learning experiences for learners at every stage of training.   Guest Speakers:   Dr. Sarah Eggers Russell, PharmD, BCACP, CPP   UNC Health REX  Dr. Kimberly James, PharmD  UF Health    Host:   Carolyn Liptak, MBA, BS Pharm Pharmacy Executive Director, Regulatory Compliance Vizient Center for Pharmacy Practice Excellence   Show Notes:  00:05 - What Is Layered Learning? Definition of layered learning and its role in pharmacy education How teaching, mentorship, and patient care occur simultaneously Benefits for learners, preceptors, and patients 01:08 - Residency Program Overviews UNC Health Rex ambulatory care residency program UF Health pediatric pharmacy residency program Opportunities for students, residents, and advanced learners across diverse practice settings 02:22 - How Layered Learning Works in Practice Senior learners mentoring junior learners under pharmacist supervision Developing teaching skills and professional behaviors Expanding direct patient care opportunities while supporting preceptor workloads 03:33 - Defining Roles and Responsibilities Setting expectations before the rotation begins Assessing learner readiness for teaching responsibilities Creating structured orientation processes for all learners Providing feedback and evaluation opportunities for resident preceptors 05:55 - Adapting to Different Learning Styles Tailoring rotations to individual learner needs Gradually increasing clinical responsibilities Using regular feedback sessions and midpoint evaluations Building confidence through progressive independence 08:20 - Building Successful Layered Learning Experiences Differences between primary and co precepting models Leveraging learners to expand patient access and clinical services Using shared precepting across diverse practice environments Creating opportunities for leadership and teaching development 10:42 - Keeping Learners Engaged in Ambulatory Care Managing clinic schedules and patient encounters Evidence based patient case presentations Topic discussions, drug information requests, and interdisciplinary shadowing opportunities Exposure to diagnostic testing and specialty practice areas 12:13 - Structuring Layered Learning in the Inpatient Setting Working across multiple specialty consult services Presenting to interdisciplinary healthcare teams Shadowing opportunities with nursing and other disciplines Using projects to improve patient care and learner engagement 13:39 - Advice for First Time Preceptors Maintaining flexibility and adaptability Meeting learners where they are in their development Keeping communication open through regular check ins Encouraging learners to embrace new challenges and teaching opportunities 14:51 - The Lasting Impact of Layered Learning Benefits for junior learners, advanced learners, and preceptors Strengthening interdisciplinary collaboration Increasing awareness of pharmacy residency programs Bringing fresh perspectives and new ideas into clinical practice 16:34 - Resources and What's Next ASHP Guide for Best Practices of Layered Learning Upcoming Vizient Layered Learning Toolkit currently in development   Links and Resources:  Residency-Guide_Best-Practices-for-Resident-Engagement-in-LLM_Final.ashx    Subscribe Today!  Apple Podcasts  Spotify  YouTube  RSS Feed   

Send us Fan MailSchedule an Rx AssessmentWelcome to the inaugural Bottom Line Catch Up and Hawaiian Shirt Friday at Sykes & Company, and the team is back together including Bonnie, who survived a grizzly bear encounter in Yellowstone for a wide-ranging post-tax season catch-up.In this episode, we break down the hottest topics right now in pharmacy including:Transition conversationsMulti-store expansion opportunitiesWhy peptides may be the biggest thing to ever hit compounding pharmacyAnd more!Stay connected with us: FacebookTwitterLinkedInScotty Sykes – CPA, CFP LinkedInScotty Sykes – CPA, CFP TwitterBonnie Bond – CPA LinkedInBonnie Bond – CPA TwitterMore resources on this topic:Podcast – Driving Independent Pharmacy Profitability in 2026 with Nicolette Mathey, PharmD, CEO of Atrium24Podcast – 2026 Quarter 2 Pharmacy UpdatePodcast – Building a Super Culture in Your Pharmacy

On this episode of This Week in Pharmacy, we bring together three powerful voices shaping the future of pharmacy, independent practice, functional medicine, and healthcare transformation.   First, we welcome Kris Rhea, MBA, Contributing Editor with Dispense Times, a digital publication dedicated to supporting independent community pharmacy owners across the United States. Kris brings a business-focused perspective on pharmacy operations, growth strategy, workflow efficiency, data-driven decision-making, and market positioning. His work with Dispense Times helps independent pharmacists navigate today's rapidly changing healthcare landscape, including PBM pressures, evolving patient expectations, regulatory challenges, and the need for sustainable business models that keep local pharmacies strong.   We also speak with James Maskell, founder of Evolution of Medicine, an organization built to inspire, equip, and unite functional and integrative medicine practitioners. Evolution of Medicine provides education, practice-building resources, and community for clinicians who are working to build thriving practices rooted in whole-person care. James brings a national perspective on the movement toward functional medicine, community-based care, prevention, and new models that empower practitioners to better serve patients beyond the limitations of conventional healthcare.   Our third guest is Marina Buksov, PharmD, a pharmacist, herbalist, educator, podcast host, and holistic health consultant. After earning her PharmD from St. John's University and graduating Summa Cum Laude in 2013, Marina entered pharmacy eager to serve patients, but quickly recognized that traditional allopathic pharmacy did not fully align with her deeper calling to help people thrive through prevention, root-cause care, plant medicine, and sustainable wellness strategies. Her experience behind the pharmacy counter and as a patient herself inspired her to pursue health coaching, nutrition, functional medicine, and clinical herbalism. Today, Marina helps pharmacists and healthcare professionals explore natural-minded career paths and build meaningful work that bridges pharmacology, herbal therapeutics, and holistic care.   Together, this episode explores where pharmacy is headed: independent pharmacy survival, business model innovation, functional medicine, patient-centered care, pharmacist reinvention, and the growing demand for healthcare professionals who can connect science, prevention, and real-world practice.   Listen to This Week in Pharmacy on the Pharmacy Podcast Network. Pharmacy's future is being built by those willing to challenge the current model, support independent practice, and expand the role of pharmacists as trusted healthcare providers.

Why Prescriptions Weren't Enough: A Clinical Pharmacist's Wake-Up Call! Dr. Curt Dearing with Nutrition World: Curt Dearing-Clinical Pharmacist, Pharm.D., Integrative Pharmacy Specialist (our conversation does not replace your advice from your doctor - we are not giving medical advice or claiming to cure illness - we are sharing personal stories - please always consult your doctor before you start any supplements or stop taking any medications! This is for entertainment purposes) ===== THANK YOU TO OUR SPONSORS: (Welcome to our NEW sponsor) Signal Investigations: https://www.signalpi.com/ Nutrition World: https://nutritionw.com/ Vascular Institute of Chattanooga: https://www.vascularinstituteofchattanooga.com/ The Barn Nursery: https://www.barnnursery.com/ Optimize U Chattanooga: https://optimizeunow.com/chattanooga/ Guardian Investment Advisors: https://giaplantoday.com/ Alchemy Medspa and Wellness Center: http://www.alchemychattanooga.com/ Our House Studio: https://ourhousestudiosinc.com/ Team Montieth Real Estate - Lori Montieth: https://www.findchattanoogarealestate.com/ Ballinger and Associates - Risk Management: https://ballingerandassociates.com/ AirSpace Acoustics: https://www.airspaceacoustics.com/ BWELL4EVER: Labs and IV Therapies: https://www.bwell4ever.org/ ALL THINGS JEFF STYLES: www.thejeffstyles.com PART OF THE NOOGA PODCAST NETWORK: www.noogapodcasts.com Please consider leaving us a review on Apple and giving us a share to your friends! This podcast is powered by ZenCast.fm